Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

A breakthrough study from Keck Medicine of USC may have found a powerful new triple therapy for glioblastoma, one of the ...

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that ...